Aerie Pharmaceuticals
Aerie Pharmaceuticals Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two lead product candidates are once-daily therapies for lowering intraocular pressure with mechanisms to treat patients with glaucoma or ocular hypertension.
| Company type | Subsidiary |
|---|---|
Traded as | Nasdaq: AERI |
| Industry |
|
| Founded | 2005 |
| Founders |
|
| Headquarters | Durham, North Carolina, U.S. |
| Parent | Alcon |
| Website | aeriepharma |
In August 2022, Swiss eye-care firm Alcon agreed to buy Aerie Pharmaceuticals for US$770 million. The acquisition completed in November 2022.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.